NCT06967103View on ClinicalTrials.gov

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

238

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 30, 2029

Conditions

Breast CancerHR+/HER2- Breast Cancer

Interventions

DRUG

QL1706

bispecific antibody targeting PD-1 and CLTA-4

DRUG

Nab-PE

Nab-paclitaxel+Epirubicin

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV